Blog
About

  • Record: found
  • Abstract: found
  • Article: not found

Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation.

Read this article at

ScienceOpenPublisherPubMed
Bookmark
      There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

      Abstract

      The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established.

      Related collections

      Author and article information

      Affiliations
      [1 ] From the Office of Surveillance and Epidemiology (D.J.G., M.E.R., K.M., M.R.G., M.H.), Office of Biostatistics (R.Z., M.L.), and Office of New Drugs (M.R.S.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD; Acumen LLC, Burlingame, CA (M.W., T.S., T.E.M.); Department of Economics, Stanford University, Stanford, CA (T.E.M.); and Centers for Medicare & Medicaid Services, Washington, DC (C.W., J.A.K.). david.graham1@fda.hhs.gov.
      [2 ] From the Office of Surveillance and Epidemiology (D.J.G., M.E.R., K.M., M.R.G., M.H.), Office of Biostatistics (R.Z., M.L.), and Office of New Drugs (M.R.S.), Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD; Acumen LLC, Burlingame, CA (M.W., T.S., T.E.M.); Department of Economics, Stanford University, Stanford, CA (T.E.M.); and Centers for Medicare & Medicaid Services, Washington, DC (C.W., J.A.K.).
      Journal
      Circulation
      Circulation
      1524-4539
      0009-7322
      Jan 13 2015
      : 131
      : 2
      25359164
      CIRCULATIONAHA.114.012061
      10.1161/CIRCULATIONAHA.114.012061
      © 2014 American Heart Association, Inc.

      Comments

      Comment on this article